Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?

被引：0

作者：

Keizman, Daniel

Ish-Shalom, Maya

Maimon, Natalie

Gottfried, Maya

Pili, Roberto

Hammers, Hans J.

Eisenberger, Mario A.

Sinibaldi, Victoria J.

Boursi, Ben

Weitzen, Rony

Hayat, Henry

Peer, Avivit

Neumann, Avivit

Kovel, Svetlana

Sella, Avishay

Mermershtain, Wilmosh

Rouvinov, Keren

Berger, Raanan

Carducci, Michael Anthony

机构：

[1] Tel Aviv Univ, Genitourinary Oncol Serv, Div Oncol, Meir Med Ctr,Sackler Sch Med, Kefar Sava, Israel

[2] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel

[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[4] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[6] Chaim Sheba Med Ctr, Ramat Gan, Israel

[7] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel

[8] Wolfson Med Ctr, Dept Oncol, Holon, Israel

[9] Rambam Hlth Care Campus, Haifa, Israel

[10] Rambam Med Ctr, Dept Oncol, Haifa, Israel

[11] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel

[12] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel

[13] Soroka Med Ctr, Beer Sheva, Israel

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e15598

引用

页数：1

共 50 条

[1] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
Keizman, Daniel
Ish-Shalom, Maya
Maimon, Natalie
Gottfried, Maya
Pili, Roberto
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Boursi, Ben
Weitzen, Rony
Hayat, Henry
Peer, Avivit
Neumann, Avivit
Kovel, Svetlana
Sella, Avishay
Mermershtain, Wilmosh
Roubinov, Keren
Berger, Raanan
Carducci, Michael Anthony
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[2] Outcome of octogenarian versus (vs) young patients (pts) with metastatic renal cell carcinoma (mRCC), treated with sunitinib (su).
Kushnir, Igal
Rosenbaum, Eli
Sarid, David Leonid
Sella, Avishay
Gottfried, Maya
Maimon, Natalie
Peer, Avivit
Neumann, Avivit
Neiman, Victoria
Kovel, Svetlana
Gez, Eliahu
Mermershtain, Wilmosh
Rouvinov, Keren
Carducci, Michael Anthony
Eisenberger, Mario A.
Hammers, Hans J.
Sinibaldi, Victoria J.
Berger, Raanan
Keizman, Daniel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] Outcome of octogenarian versus (vs) young patients (pts) with metastatic renal cell carcinoma (mRCC), treated with sunitinib (su).
Kushnir, Igal
Rosenbaum, Eli
Sella, Avishay
Sarid, David
Gottfried, Maya
Maimon, Natalie
Peer, Avivit
Neumann, Avivit
Neiman, Victoria
Kovel, Svetlana
Gez, Eliahu
Mermershtain, Wilmosh
Rouvinov, Keren
Carducci, Michael Anthony
Eisenberger, Mario A.
Hammers, Hans J.
Sinibaldi, Victoria J.
Berger, Raanan
Keizman, Daniel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[4] Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su)
Berger, Raanan
Keizman, Daniel
Ish-Shalom, Maya
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Pili, Roberto
Boursi, Ben
Maimon, Natalie
Gottfried, Maya
Hayat, Henry
Peer, Avivit
Kovel, Svetlana
Sella, Avishay
Carducci, Michael Anthony
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[5] CARDIOTOXICITY IN METASTATIC RENAL CELL CARCINOMA (mRCC) PATIENTS TREATED WITH SUNITINIB (SU)
Ballatore, Valentina
Prati, Veronica
Ruatta, Fiorella
Galizia, Danilo
Grignani, Giovanni
Aglietta, Massimo
Ortega, Cinzia
[J]. ANTICANCER RESEARCH, 2012, 32 (05) : 1876 - 1877
[6] Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC).
Cella, David
Davis, Mellar P.
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Hahn, Elizabeth A.
Korytowsky, Beata
Bhattacharyya, Helen
Sandin, Rickard
Beaumont, Jennifer L.
Matczak, Ewa
Motzer, Robert John
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[7] Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU)
Prati, Veronica
Ortega, Cinzia
Ballatore, Valentina
Galizia, Danilo
Ruatta, Fiorella
Bonzano, Alessandro
Aliberti, Sandra
Grignani, Giovanni
Aglietta, Massimo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[8] Metformin (met) use and outcome of sunitinib (Su) treatment (tx) in diabetic patients (pts) with metastatic renal cell carcinoma (mRCC)
Keizman, Daniel
Ish-Shalom, Maya
Peer, Avivit
Chish, Adi
Sella, Avishay
Gottfried, Maya
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Neiman, Victoria
Rosenbaum, Eli
Sarid, David
Gez, Eliahu
Mermershtain, Wilmosh
Rouvinov, Keren
Weitzen, Rony
Weitzen, Rony
Berger, Raanan
Carducci, Michael Anthony
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[9] Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib?
Keizman, Daniel
Ish-Shalom, Maya
Maimon, Natalie
Gottfried, Maya
Pili, Roberto
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Boursi, Ben
Weitzen, Rony
Hayat, Henry
Peer, Avivit
Neumann, Avivit
Kovel, Svetlana
Sella, Avishay
Mermershtain, Wilmosh
Roubinov, Keren
Carducci, Michael Anthony
Berger, Raanan
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[10] Hand-foot syndrome (HFS), a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU)
Bensalem, A.
Ammari, A.
Dahdouh, A.
Saadi, A.
Bouzid, K.
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S654 - S654

← 1 2 3 4 5 →